Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study.

Barrington SF, Phillips EH, Counsell N, Hancock B, Pettengell R, Johnson P, Townsend W, Culligan D, Popova B, Clifton-Hadley L, McMillan A, Hoskin P, O'Doherty MJ, Illidge T, Radford J.

J Clin Oncol. 2019 Jul 10;37(20):1732-1741. doi: 10.1200/JCO.18.01799. Epub 2019 May 21.

PMID:
31112475
2.

Novel Methods to Improve the Efficiency of Radioimmunotherapy for Non-Hodgkin Lymphoma.

Eskian M, Khorasanizadeh M, Zinzani PL, Illidge TM, Rezaei N.

Int Rev Immunol. 2019;38(2):79-91. doi: 10.1080/08830185.2019.1588266. Epub 2019 Mar 31.

PMID:
30931651
3.

Evaluation of apoptosis imaging biomarkers in a genetic model of cell death.

Vassileva V, Stribbling SM, Barnes C, Carroll L, Braga M, Abrahams J, Heinzmann K, Haegeman C, MacFarlane M, Simpson KL, Dive C, Honeychurch J, Illidge TM, Aboagye EO.

EJNMMI Res. 2019 Feb 19;9(1):18. doi: 10.1186/s13550-019-0487-8.

4.

The management of primary mediastinal B-cell lymphoma: a British Society for Haematology Good Practice Paper.

Cwynarski K, Marzolini MAV, Barrington SF, Follows G, Illidge T, Stern S, Davies A; British Society for Haematology Guidelines.

Br J Haematol. 2019 May;185(3):402-409. doi: 10.1111/bjh.15731. Epub 2019 Jan 4. No abstract available.

PMID:
30609016
5.

British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018.

Gilson D, Whittaker SJ, Child FJ, Scarisbrick JJ, Illidge TM, Parry EJ, Mohd Mustapa MF, Exton LS, Kanfer E, Rezvani K, Dearden CE, Morris SL.

Br J Dermatol. 2019 Mar;180(3):496-526. doi: 10.1111/bjd.17240. Epub 2018 Dec 17. No abstract available.

PMID:
30561020
6.

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.

Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L; ECHELON-2 Study Group.

Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4. Erratum in: Lancet. 2019 Jan 19;393(10168):228.

PMID:
30522922
7.

Clinical Development of Novel Drug-Radiotherapy Combinations.

Ahmad SS, Crittenden MR, Tran PT, Kluetz PG, Blumenthal GM, Bulbeck H, Baird RD, Williams KJ, Illidge T, Hahn SM, Lawrence TS, Spears PA, Walker AJ, Sharma RA.

Clin Cancer Res. 2019 Mar 1;25(5):1455-1461. doi: 10.1158/1078-0432.CCR-18-2466. Epub 2018 Nov 29.

PMID:
30498095
8.

Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom.

Bröckelmann PJ, McMullen S, Wilson JB, Mueller K, Goring S, Stamatoullas A, Zagadailov E, Gautam A, Huebner D, Dalal M, Illidge T.

Br J Haematol. 2019 Jan;184(2):202-214. doi: 10.1111/bjh.15566. Epub 2018 Sep 21.

9.

The influence of radiation in the context of developing combination immunotherapies in cancer.

Honeychurch J, Illidge TM.

Ther Adv Vaccines Immunother. 2017 Dec;5(6):115-122. doi: 10.1177/2051013617750561. Epub 2018 Jan 24. Review.

10.

Revisiting the role of radiotherapy in Hodgkin lymphoma to augment systemic immunity.

Walshaw RC, Illidge TM.

Leuk Lymphoma. 2018 Nov;59(11):2519-2520. doi: 10.1080/10428194.2018.1464160. Epub 2018 Jun 22. No abstract available.

PMID:
29932777
11.

Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Eichenauer DA, Aleman BMP, André M, Federico M, Hutchings M, Illidge T, Engert A, Ladetto M; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv19-iv29. doi: 10.1093/annonc/mdy080. No abstract available.

PMID:
29796651
12.

How do we move towards a personalised approach in the treatment of Early Hodgkin lymphoma?

Maraldo MV, Illidge TM.

Br J Haematol. 2018 Jul;182(2):163-164. doi: 10.1111/bjh.15256. Epub 2018 May 22. No abstract available.

PMID:
29785756
13.

The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group.

Constine LS, Yahalom J, Ng AK, Hodgson DC, Wirth A, Milgrom SA, Mikhaeel NG, Eich HT, Illidge T, Ricardi U, Dieckmann K, Moskowitz CH, Advani R, Mauch PM, Specht L, Hoppe RT.

Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1100-1118. doi: 10.1016/j.ijrobp.2018.01.011. Epub 2018 Jan 9. Review.

14.

Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas.

Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Uttarwar M, Lee SY, Ren H, Kennedy DA, Shustov AR.

Blood. 2018 May 10;131(19):2120-2124. doi: 10.1182/blood-2017-12-821009. Epub 2018 Mar 5.

15.

Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group.

Ng AK, Yahalom J, Goda JS, Constine LS, Pinnix CC, Kelsey CR, Hoppe B, Oguchi M, Suh CO, Wirth A, Qi S, Davies A, Moskowitz CH, Laskar S, Li Y, Mauch PM, Specht L, Illidge T.

Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):652-669. doi: 10.1016/j.ijrobp.2017.12.005. Review.

PMID:
29413279
16.

Pembrolizumab in Combination with Radiotherapy for Metastatic Melanoma - Introducing the PERM Trial.

Yip K, Melcher A, Harrington K, Illidge T, Nobes J, Webster A, Smith D, Lorigan P, Nathan P, Larkin J.

Clin Oncol (R Coll Radiol). 2018 Apr;30(4):201-203. doi: 10.1016/j.clon.2018.01.001. No abstract available.

PMID:
29402599
17.

Recommendations for the clinical management of the elderly patient with malignant lymphoma.

Specht L, Aleman B, Eich H, Illidge TM, Kirova Y, Mikhaeel NG, Ricardi U, Yahalom J; International Lymphoma Radiation Oncology Group (ILROG).

Ann Oncol. 2018 Apr 1;29(4):1069-1070. doi: 10.1093/annonc/mdy029. No abstract available.

18.

Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms.

Kordbacheh T, Honeychurch J, Blackhall F, Faivre-Finn C, Illidge T.

Ann Oncol. 2018 Feb 1;29(2):301-310. doi: 10.1093/annonc/mdx790. Review.

PMID:
29309540
19.

The anti-PD-1 era - an opportunity to enhance radiotherapy for patients with bladder cancer.

Walshaw RC, Honeychurch J, Illidge TM, Choudhury A.

Nat Rev Urol. 2018 Apr;15(4):251-259. doi: 10.1038/nrurol.2017.172. Epub 2017 Oct 31. Review.

PMID:
29089607
20.

Akt inhibition improves long-term tumour control following radiotherapy by altering the microenvironment.

Searle EJ, Telfer BA, Mukherjee D, Forster DM, Davies BR, Williams KJ, Stratford IJ, Illidge TM.

EMBO Mol Med. 2017 Dec;9(12):1646-1659. doi: 10.15252/emmm.201707767.

21.

Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany.

Zagadailov EA, Corman S, Chirikov V, Johnson C, Macahilig C, Seal B, Dalal MR, Bröckelmann PJ, Illidge T.

Leuk Lymphoma. 2018 Jun;59(6):1413-1419. doi: 10.1080/10428194.2017.1382698. Epub 2017 Oct 18.

PMID:
29045163
22.

Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.

Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Fenton K, Huebner D, Pinelli JM, Kennedy DA, Shustov A.

Blood. 2017 Dec 21;130(25):2709-2717. doi: 10.1182/blood-2017-05-780049. Epub 2017 Oct 3. Erratum in: Blood. 2018 Jul 26;132(4):458-459.

23.

Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study.

Bröckelmann PJ, Zagadailov EA, Corman SL, Chirikov V, Johnson C, Macahilig C, Seal B, Dalal MR, Illidge T.

Eur J Haematol. 2017 Dec;99(6):553-558. doi: 10.1111/ejh.12973. Epub 2017 Oct 16.

PMID:
28949403
24.

A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.

Cheadle EJ, Lipowska-Bhalla G, Dovedi SJ, Fagnano E, Klein C, Honeychurch J, Illidge TM.

Leukemia. 2017 Oct;31(10):2278. doi: 10.1038/leu.2017.218. Epub 2017 Jul 28.

PMID:
28751765
25.

Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade.

Dovedi SJ, Cheadle EJ, Popple AL, Poon E, Morrow M, Stewart R, Yusko EC, Sanders CM, Vignali M, Emerson RO, Robins HS, Wilkinson RW, Honeychurch J, Illidge TM.

Clin Cancer Res. 2017 Sep 15;23(18):5514-5526. doi: 10.1158/1078-0432.CCR-16-1673. Epub 2017 May 22.

26.

Immune Checkpoint Inhibitors in Lung Cancer - An Unheralded Opportunity?

Marshall R, Popple A, Kordbacheh T, Honeychurch J, Faivre-Finn C, Illidge T.

Clin Oncol (R Coll Radiol). 2017 Apr;29(4):207-217. doi: 10.1016/j.clon.2016.12.003. Epub 2017 Jan 4. Review.

PMID:
28063623
27.

A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.

Cheadle EJ, Lipowska-Bhalla G, Dovedi SJ, Fagnano E, Klein C, Honeychurch J, Illidge TM.

Leukemia. 2017 Jul;31(7):1611-1621. doi: 10.1038/leu.2016.352. Epub 2017 Nov 28. Erratum in: Leukemia. 2017 Jul 28;:.

28.

Stereotactic ablative radiotherapy and immunotherapy combinations: turning the future into systemic therapy?

Walshaw RC, Honeychurch J, Illidge TM.

Br J Radiol. 2016 Oct;89(1066):20160472. doi: 10.1259/bjr.20160472. Epub 2016 Sep 14. Review.

29.

Immunotherapy with radiotherapy in urological malignancies.

Mehta S, Illidge T, Choudhury A.

Curr Opin Urol. 2016 Nov;26(6):514-22. doi: 10.1097/MOU.0000000000000335. Review.

PMID:
27552139
30.

Radiotherapy and Immunotherapy Combinations in Non-small Cell Lung Cancer: A Promising Future?

Hanna GG, Illidge T.

Clin Oncol (R Coll Radiol). 2016 Nov;28(11):726-731. doi: 10.1016/j.clon.2016.07.014. Epub 2016 Aug 9. Review.

PMID:
27519157
31.

Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Vitolo U, Seymour JF, Martelli M, Illerhaus G, Illidge T, Zucca E, Campo E, Ladetto M; ESMO Guidelines Committee.

Ann Oncol. 2016 Sep;27(suppl 5):v91-v102. Epub 2016 Jul 4. No abstract available.

PMID:
27377716
32.

Clinical development of new drug-radiotherapy combinations.

Sharma RA, Plummer R, Stock JK, Greenhalgh TA, Ataman O, Kelly S, Clay R, Adams RA, Baird RD, Billingham L, Brown SR, Buckland S, Bulbeck H, Chalmers AJ, Clack G, Cranston AN, Damstrup L, Ferraldeschi R, Forster MD, Golec J, Hagan RM, Hall E, Hanauske AR, Harrington KJ, Haswell T, Hawkins MA, Illidge T, Jones H, Kennedy AS, McDonald F, Melcher T, O'Connor JP, Pollard JR, Saunders MP, Sebag-Montefiore D, Smitt M, Staffurth J, Stratford IJ, Wedge SR; NCRI CTRad Academia-Pharma Joint Working Group.

Nat Rev Clin Oncol. 2016 Oct;13(10):627-42. doi: 10.1038/nrclinonc.2016.79. Epub 2016 Jun 1.

33.

Antitumor Efficacy of Radiation plus Immunotherapy Depends upon Dendritic Cell Activation of Effector CD8+ T Cells.

Dovedi SJ, Lipowska-Bhalla G, Beers SA, Cheadle EJ, Mu L, Glennie MJ, Illidge TM, Honeychurch J.

Cancer Immunol Res. 2016 Jul;4(7):621-630. doi: 10.1158/2326-6066.CIR-15-0253. Epub 2016 May 30.

34.

Guidelines for the management of diffuse large B-cell lymphoma.

Chaganti S, Illidge T, Barrington S, Mckay P, Linton K, Cwynarski K, McMillan A, Davies A, Stern S, Peggs K; British Committee for Standards in Haematology.

Br J Haematol. 2016 Jul;174(1):43-56. doi: 10.1111/bjh.14136. Epub 2016 May 16. No abstract available.

PMID:
27196701
35.

Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies.

Lipowska-Bhalla G, Fagnano E, Illidge TM, Cheadle EJ.

Leuk Lymphoma. 2016;57(6):1269-80. doi: 10.3109/10428194.2016.1157874. Epub 2016 Apr 6. Review.

PMID:
27050042
36.

Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy.

Dovedi SJ, Adlard AL, Ota Y, Murata M, Sugaru E, Koga-Yamakawa E, Eguchi K, Hirose Y, Yamamoto S, Umehara H, Honeychurch J, Cheadle EJ, Hughes G, Jewsbury PJ, Wilkinson RW, Stratford IJ, Illidge TM.

Oncotarget. 2016 Mar 29;7(13):17035-46. doi: 10.18632/oncotarget.7928.

37.

Re-Examining the Role of Radiation Therapy for Diffuse Large B-Cell Lymphoma in the Modern Era.

Ng AK, Dabaja BS, Hoppe RT, Illidge T, Yahalom J.

J Clin Oncol. 2016 May 1;34(13):1443-7. doi: 10.1200/JCO.2015.64.9418. Epub 2016 Feb 22. No abstract available.

PMID:
26903576
38.

Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study.

Illidge TM, McKenzie HS, Mayes S, Bates A, Davies AJ, Pettengell R, Stanton L, Cozens K, Hampson G, Dive C, Zivanovic M, Tipping J, Gallop-Evans E, Radford JA, Johnson PW.

Br J Haematol. 2016 Apr;173(2):274-82. doi: 10.1111/bjh.13954. Epub 2016 Feb 5.

PMID:
26849853
39.

Turning Radiotherapy into an Effective Systemic Anti-cancer Treatment in Combination with Immunotherapy.

Illidge T.

Clin Oncol (R Coll Radiol). 2015 Dec;27(12):696-9. doi: 10.1016/j.clon.2015.09.001. Epub 2015 Sep 26. No abstract available.

PMID:
26414754
40.

PET-Directed Therapy for Hodgkin's Lymphoma.

Radford J, Illidge T, Barrington S.

N Engl J Med. 2015 Jul 23;373(4):392. doi: 10.1056/NEJMc1506340. No abstract available.

PMID:
26200987
41.

Obinutuzumab in hematologic malignancies: lessons learned to date.

Illidge T, Klein C, Sehn LH, Davies A, Salles G, Cartron G.

Cancer Treat Rev. 2015 Nov;41(9):784-92. doi: 10.1016/j.ctrv.2015.07.003. Epub 2015 Jul 14. Review.

43.

Balancing Risks in Developing a Personalised Approach to the Treatment of Early Hodgkin Lymphoma: Have We Got the Balance Right?

Illidge T.

Clin Oncol (R Coll Radiol). 2015 Aug;27(8):454-6. doi: 10.1016/j.clon.2015.05.007. Epub 2015 Jun 21. No abstract available.

PMID:
26108883
44.

Personalised approach to treating early Hodgkin's lymphoma.

Illidge T.

BMJ. 2015 Jun 2;350:h2927. doi: 10.1136/bmj.h2927. No abstract available.

PMID:
26038281
45.

Consensus guidelines for the detection of immunogenic cell death.

Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, Formenti SC, Fučíková J, Gabriele L, Gaipl US, Galon J, Garg A, Ghiringhelli F, Giese NA, Guo ZS, Hemminki A, Herrmann M, Hodge JW, Holdenrieder S, Honeychurch J, Hu HM, Huang X, Illidge TM, Kono K, Korbelik M, Krysko DV, Loi S, Lowenstein PR, Lugli E, Ma Y, Madeo F, Manfredi AA, Martins I, Mavilio D, Menger L, Merendino N, Michaud M, Mignot G, Mossman KL, Multhoff G, Oehler R, Palombo F, Panaretakis T, Pol J, Proietti E, Ricci JE, Riganti C, Rovere-Querini P, Rubartelli A, Sistigu A, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Sukkurwala AQ, Tartour E, Thorburn A, Thorne SH, Vandenabeele P, Velotti F, Workenhe ST, Yang H, Zong WX, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Dec 13;3(9):e955691. eCollection 2014 Oct. Review.

46.

Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.

Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, Wimperis J, Culligan D, Popova B, Smith P, McMillan A, Brownell A, Kruger A, Lister A, Hoskin P, O'Doherty M, Barrington S.

N Engl J Med. 2015 Apr 23;372(17):1598-607. doi: 10.1056/NEJMoa1408648.

47.

Immuno-regulatory antibodies for the treatment of cancer.

Honeychurch J, Cheadle EJ, Dovedi SJ, Illidge TM.

Expert Opin Biol Ther. 2015 Jun;15(6):787-801. doi: 10.1517/14712598.2015.1036737. Epub 2015 Apr 16. Review.

PMID:
25882106
48.

The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant.

Reynders K, Illidge T, Siva S, Chang JY, De Ruysscher D.

Cancer Treat Rev. 2015 Jun;41(6):503-10. doi: 10.1016/j.ctrv.2015.03.011. Epub 2015 Mar 28. Review.

49.

Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group.

Specht L, Dabaja B, Illidge T, Wilson LD, Hoppe RT; International Lymphoma Radiation Oncology Group.

Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):32-9. doi: 10.1016/j.ijrobp.2015.01.008.

50.

Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group.

Yahalom J, Illidge T, Specht L, Hoppe RT, Li YX, Tsang R, Wirth A; International Lymphoma Radiation Oncology Group.

Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):11-31. doi: 10.1016/j.ijrobp.2015.01.009.

Supplemental Content

Loading ...
Support Center